STERIS plc (STE)

In the past six months, STERIS Plc's stock has been impacted by several events. The company exceeded Q1 2026 estimates, reporting $1.39 billion in revenue and $2.34 adjusted earnings per share, driven by strong demand in healthcare and sterilization services. Despite the earnings beat, the company noted increased tariff impacts and raised its fiscal year 2026 revenue growth outlook. As of January 2, 2026, the share price was $250.04, marking a 22.56% increase from January 6, 2025. The stock was upgraded to "Buy" in December 2025. Renato Tamaro, Sr. VP General Counsel and Secretary, sold shares on November 17, 2025. STERIS plc acquired Medik Hospital Design GmbH.

Demand for STERIS Plc's products and services is characterized by a stable and inelastic curve. Approximately 80% of the company's revenue is derived from recurring services and consumables, with 20% from capital equipment, contributing to stable demand. While bioprocessing demand experienced some stabilization in the fourth quarter of fiscal year 2024, a return to meaningful growth in this area is anticipated in the second half of fiscal year 2025. The Healthcare segment has consistently outperformed.

STERIS Plc is a global leader in infection prevention, contamination control, and procedural support products and services, operating primarily within the medical equipment sector. The company serves healthcare, pharmaceutical, medical device, life sciences, and industrial customers, providing innovative healthcare and life science solutions. Its major product offerings are diversified across three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, including capital equipment, consumables, and services.

STERIS Plc operates in over 100 countries worldwide, with its operational headquarters in Mentor, Ohio, USA, despite being legally registered in Dublin, Ireland. The company has a global network of manufacturing facilities, sales offices, service centers, and R&D sites across North America, Europe, Asia-Pacific, Latin America, and other international markets. Key operational hubs include Tullamore, Ireland, Leicester/Harrogate, United Kingdom, and Plymouth, Minnesota, USA. Recent expansions include facilities in Batu Kawan, Malaysia, Suzhou, China, and Edmonton, Alberta, Canada.

In the past year, STERIS Plc has maintained a strong brand reputation, consistently recognized for its role in healthcare and as an employer. The company was listed on Forbes' "America's Best Employers for Women" (2025) and on the "Global 2000" (2025). Earlier recognitions include "America's Best Employers By State" (2023) and "World's Best Employers" (2022). The company is generally viewed as a stable medical device stock and a global leader in infection prevention.

STERIS Plc is predominantly owned by institutional investors, who collectively hold over 93% of the company's shares. Vanguard Group Inc. is the largest single shareholder, followed by BlackRock Inc. Other significant institutional owners include Massachusetts Financial Services Co /ma/, State Street Corp, Morgan Stanley, Generation Investment Management Llp, Geode Capital Management, Llc, and various Vanguard index funds. Individual ownership accounts for a smaller portion.